Please use this identifier to cite or link to this item:
|Title:||Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.|
|Citation:||Breast Cancer Res. Treat..2017 Sep;(165)2:329-341|
|Abstract:||Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.